IP Library Patent Application 11351462
Patent Application
App. No. 11/351,462

Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/351,462
Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

Claims (13)

1 . An isolated biopolymer marker consisting of SEQ ID NO:3.

2 . A method for determining in a patient sample, the presence of an isolated biopolymer marker consisting of SEQ ID NO: 3 which is linked to insulin resistance comprising:

(a) obtaining a sample from a patient;

(b) conducting mass spectrometric analysis on said sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum profiles of said isolated biopolymer marker consisting of SEQ ID NO:3 to mass spectrum profiles of peptides obtained and analyzed from said sample; and

(c) confirming the presence of said isolated biopolymer marker consisting of SEQ ID NO:3 in said sample displaying a peak profile at about 1212 daltons in said mass spectrum profile;

wherein the presence of said isolated biopolymer marker consisting of SEQ ID NO:3 is indicative of a link to insulin resistance.

3 . The method of claim 2 , wherein said sample is an unfractionated body fluid or a tissue sample.

4 . The method of claim 2 , wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

5 . The method of claim 2 , wherein said mass spectrometric analysis is selected from the group consisting of Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS, TOF-TOF, ESI-Q-TOF and ION-TRAP.

6 . The method of claim 2 , wherein said patient is a human.

7 . A kit for determining the presence of an isolated biopolymer marker consisting of SEQ ID NO:3 comprising: (a) a peptide consisting of SEQ ID NO:3, and (b) an antibody that binds to said peptide in a sample from a patient.

8 . The kit of claim 7 , wherein said antibody is immobilized on a solid support.

9 . The kit of claim 7 , wherein said antibody is labeled.

Assignments (1)
GRANT OF SECURITY INTEREST Recorded Jul 25, 2008
From: NANOGEN, INC.
To: PORTSIDE GROWTH & OPPORTUNITY FUND, AS COLLATERAL AGENT
Reel/Frame 021291/0605 →